Is Hepatitis B entering the era of personalised medicine?

A.ThompsonA.Thompson
M.DouglasM.Douglas
BulletArticle
Infectious Diseases Liver disease & HCC
공유:
링크 복사
Is Hepatitis B entering the era of personalised medicine_thumbnail

New cure strategies for Hepatitis B are in development. Emerging data suggests a key role for biomarkers to identify subsets of people living with Hepatitis B who are most likely to respond to treatment. In this webinar, we discussed recent advances in Hepatitis B biomarker development, and how these tools can be used to personalise the management of people living with Hepatitis B.
 

공유:
링크 복사

동일한 주제에 대한 추가 정보

AMILI brings ‘precision gut microbiomics’ to Southeast Asia

PIVKA-II drives early detection of HCC in Vietnam

권장 주제

염기서열 분석RED 2020Rare Diseases
다음 읽기
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
3 steps to mitigate the impact of interference
  • Clinician Engagement, Coagulation, Disease Area, Management
3 steps to mitigate the impact of interference
Navapun1
검사의 품질, 속도, 비용의 균형을 맞추기 위한 방법
Scroll to Top